Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function. (2019)
Attributed to:
Accelerating discovery science to clinical translation: CiC3 - The Oxford MRC CiC Pipeline
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.jaci.2019.02.015
PubMed Identifier: 30825466
Publication URI: http://europepmc.org/abstract/MED/30825466
Type: Journal Article/Review
Volume: 143
Parent Publication: The Journal of allergy and clinical immunology
Issue: 6
ISSN: 0091-6749